Diacarta, Inc.

Diacarta, Inc. is a for-profit corporate entity registered in SAM.gov, located in Hayward, California, with a current registration valid through August 27, 2026. The company specializes in providing reference laboratory services, with a specific focus on advanced medical testing related to rare medical conditions. Based on its federal contract history, Diacarta, Inc. appears to be a specialized medical diagnostics firm that works closely with federal healthcare agencies, particularly within the Veterans Affairs system.

The company has been awarded federal contracts exclusively through the Veterans Integrated Service Network 21 (VISN 21), a civilian agency within the U.S. Department of Veterans Affairs. Specifically, Diacarta, Inc. provides reference lab services focused on VEXAS syndrome, a rare inflammatory disorder. These services involve specialized medical testing, including specimen pickup, testing, reporting, and consultation services for somatic mutations of the UBA1 gene. The contracts have been awarded on a firm fixed-price basis with no specific set-aside designations, indicating open competition. Each contract has a relatively modest ceiling value, ranging from $19,104 for annual task orders to a broader Indefinite Delivery Contract (IDC) with a $200,000 ceiling.

Diacarta, Inc. holds an Indefinite Delivery Contract (IDC) with VISN 21, awarded on October 1, 2024, with an ultimate completion date of September 30, 2029. This single-award IDC is specifically structured for reference lab services related to VEXAS syndrome. Under this IDC, the company has been awarded task orders for fiscal years 2025 and 2026, each with a $19,104 ceiling value. The contract enables VISN 21 to procure specialized laboratory testing services as needed, with a focus on diagnostic testing for a specific rare medical condition. The IDC provides flexibility for the Veterans Affairs system to access Diacarta's specialized medical testing capabilities over a multi-year period.